Introduction
Graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT) and certain solid organ transplants, characterized by an immunological attack of donor-derived immune cells against recipient tissues. It remains a major determinant of morbidity and mortality following transplantation, with significant implications for long-term survival and quality of life. While advances in donor selection, conditioning regimens, and prophylactic strategies have improved outcomes, GVHD continues to pose substantial clinical challenges. This article provides a comprehensive, evidence-based review of GVHD for health professionals, focusing on pathophysiology, classification, clinical manifestations, diagnostic approaches, and current therapeutic strategies based on the most recent guidelines and clinical trial data.
Pathophysiology and Risk Factors
GVHD arises when immunocompetent donor T cells, present in the graft, recognize host antigens as foreign and mount an immune response against recipient tissues. This process involves three key phases:
- Initiation: Tissue damage from conditioning regimens (chemotherapy or radiation) releases pro-inflammatory cytokines (e.g., TNF-α, IL-1, IL-6), activating antigen-presenting cells (APCs) in the recipient.
- Activation and Expansion: Donor T cells are activated upon recognition of mismatched human leukocyte antigens (HLA) or minor histocompatibility antigens (miHA) on recipient APCs. These T cells proliferate and differentiate into effector T cells.
- Effector Phase: Activated donor T cells migrate to target organs—primarily the skin, gastrointestinal (GI) tract, and liver—causing tissue injury through direct cytotoxicity and cytokine release (e.g., IFN-γ, TNF-α).
Risk Factors for GVHD:
- HLA Disparity: The most significant risk factor. Even a single HLA mismatch increases GVHD risk, with higher rates in unrelated or mismatched donors.
- Donor Type: Unrelated donor transplants carry higher GVHD risk compared to matched sibling donors. Haploidentical and cord blood transplants also have elevated risks.
- Age: Older recipients (>40 years) and older donors (>50 years) are at increased risk for both acute and chronic GVHD.
- Graft Source: Peripheral blood stem cells (PBSCs) are associated with higher rates of chronic GVHD compared to bone marrow grafts.
- Conditioning Regimen Intensity: Myeloablative regimens increase tissue damage and GVHD risk compared to reduced-intensity conditioning (RIC).
- Sex Mismatch: Female donors to male recipients (especially multiparous females) increase GVHD risk due to anti-HLA antibodies from prior pregnancies.
- Infections and Microbiome: Gut dysbiosis and viral infections (e.g., CMV, EBV) can exacerbate inflammation and promote GVHD development.
Classification of GVHD
GVHD is broadly classified into acute GVHD (aGVHD) and chronic GVHD (cGVHD), based on timing, clinical features, and pathophysiology.
1. Acute GVHD (aGVHD)
Timing: Typically occurs within the first 100 days post-transplant, though late-onset cases (up to 180 days) are increasingly recognized.
Clinical Features:
- Skin: Maculopapular rash, often beginning on the palms, soles, or face, and spreading to the trunk and extremities. In severe cases, erythroderma or epidermal necrosis may occur. The rash may be pruritic or painful.
- Gastrointestinal Tract: Diarrhea (often >100 mL/kg/day), nausea, vomiting, and abdominal cramping. Endoscopic findings include mucosal erythema, ulceration, and friability. Severe cases may lead to malabsorption and protein-losing enteropathy.
- Liver: Jaundice, elevated bilirubin, and increased liver enzymes (ALT, AST, ALP). Histopathology reveals bile duct damage and portal tract inflammation.
Grading Systems:
- Glucksberg Criteria (Modified): Grades aGVHD from I to IV based on clinical severity in skin, GI, and liver involvement.
- NIH Consensus Criteria (2014): Widely adopted for standardization. It emphasizes clinical assessment, endoscopy, and histopathology.
Diagnosis:
- Clinical Evaluation: Detailed history and physical examination, including assessment of skin, GI, and hepatic symptoms.
- Biopsy: Gold standard for confirmation. Skin biopsies show epidermal necrosis, apoptotic keratinocytes, and lymphocytic infiltration. GI biopsies may reveal crypt apoptosis and lamina propria infiltration. Liver biopsies show bile duct injury and portal tract inflammation.
- Laboratory Tests: Elevated liver enzymes, bilirubin, and inflammatory markers (e.g., CRP, ferritin). Biomarkers such as ST2 (soluble ST2), REG3α, and TNFR1 are emerging as predictive tools for severity and response to therapy (per the Biomarker Consortium for GVHD).
- Imaging: Abdominal ultrasound or CT may detect hepatosplenomegaly, ascites, or bowel wall thickening.
Treatment of aGVHD:
First-Line Therapy:
- Corticosteroids (e.g., methylprednisolone 1–2 mg/kg/day IV or prednisone 1–2 mg/kg/day orally) remain the standard initial therapy.
- Response is assessed at 3–5 days. Patients who do not respond are classified as steroid-refractory aGVHD (SR-aGVHD), a high-risk condition with poor prognosis.
Second-Line Therapy:
- Ruxolitinib (JAK1/2 inhibitor): Approved by the FDA in 2019 for second-line treatment of SR-aGVHD based on the REACH-2 trial (NEJM, 2020), which demonstrated a 60% overall response rate versus 29% with best available therapy (BAT), with improved durability and reduced steroid dependence.
- Other Agents:
- Ibrutinib (BTK inhibitor): Approved for cGVHD, but also used in aGVHD with promising results in early trials.
- ECP (Extracorporeal Photopheresis): Effective for skin-predominant aGVHD, particularly in patients with steroid resistance.
- Mesenchymal Stromal Cells (MSCs): Emerging as a potential immunomodulatory therapy, though evidence remains limited.
- T-cell Depletion Strategies: Post-transplant cyclophosphamide (PTCy) is used in haploidentical transplants to prevent GVHD.
2. Chronic GVHD (cGVHD)
Timing: Typically develops between 90 and 600 days post-transplant, but can occur earlier or later. cGVHD is a leading cause of late non-relapse mortality and significantly impacts long-term quality of life.
Clinical Features:
- Skin: Erythematous or hyperpigmented macules, sclerotic patches, and lichenoid eruptions. Pruritus and xerosis are common. In severe cases, lichen sclerosus or sclerodermatous changes may develop.
- Oral Cavity: Lichen planus-like lesions, mucosal atrophy, and oral ulcers. These increase the risk of oral squamous cell carcinoma (OSCC), with a 5–10-fold higher risk compared to the general population. cGVHD-related OSCC is often more aggressive and associated with poorer outcomes.
- Ocular: Dry eyes (keratoconjunctivitis sicca), corneal erosions, and reduced tear production due to lacrimal gland involvement.
- GI Tract: Dysphagia, dyspepsia, and abdominal pain due to esophageal strictures or motility disorders. Chronic diarrhea may occur.
- Pulmonary: Obstructive lung disease, bronchiolitis obliterans, and restrictive lung patterns due to airway fibrosis.
- Hepatic: Elevated transaminases, portal hypertension, and hepatosplenomegaly.
- Musculoskeletal: Joint contractures, myositis, and muscle weakness.
- Hematologic: Cytopenias due to bone marrow suppression.
Diagnostic Criteria (NIH Consensus Criteria, 2014):
- Presence of at least one major criterion (e.g., skin sclerosis, oral lichen planus, or esophageal stenosis) and at least one minor criterion (e.g., dry eyes, dry mouth, or pulmonary dysfunction).
- Diagnosis requires exclusion of infection, relapse, and other causes of symptoms.
Management of cGVHD:
First-Line Therapy:
- Corticosteroids (e.g., prednisone 0.5–1 mg/kg/day) remain the cornerstone.
- Calcineurin Inhibitors (CNIs): Ciclosporin or tacrolimus are often combined with steroids to reduce steroid exposure and maintain remission.
Second-Line and Refractory Therapy:
- Ibrutinib: FDA-approved for cGVHD after failure of ≥1 prior systemic therapy. The BRIGHT trial (NEJM, 2021) demonstrated a 56% overall response rate, with significant improvement in symptoms and functional status.
- Ruxolitinib: Also effective in cGVHD, particularly for skin and GI involvement.
- Rituximab: Used in cGVHD with B-cell involvement (e.g., autoimmune phenomena).
- Sirolimus and Tacrolimus: Used as steroid-sparing agents.
- Pentostatin: For severe, steroid-refractory cases, especially in patients with lymphoproliferative features.
- Mycophenolate Mofetil (MMF): Useful for mild-moderate cGVHD.
- Extracorporeal Photopheresis (ECP): Effective for skin and pulmonary involvement, with minimal systemic toxicity.
- JAK Inhibitors (e.g., tofacitinib): Emerging role in refractory cGVHD.
- Immunoglobulin Therapy (IVIG): May be beneficial in patients with autoantibody-mediated cGVHD.
Supportive Care:
- Dental and Ophthalmologic Care: Regular screening for oral and ocular complications.
- Pulmonary Function Testing: Annual spirometry to monitor for bronchiolitis obliterans.
- Nutritional Support: Address malabsorption and weight loss.
- Psychosocial Support: cGVHD profoundly affects mental health and quality of life.
Emerging Therapies and Future Directions
- Biomarker-Guided Therapy: Integration of ST2, REG3α, and TNFR1 into clinical algorithms allows for early risk stratification and personalized treatment.
- Cellular Therapies: Regulatory T cells (Tregs) and tissue-resident memory T cells (Trm) are under investigation for GVHD prevention.
- Microbiome Modulation: Probiotics, fecal microbiota transplantation (FMT), and targeted antibiotics are being studied to restore gut homeostasis and reduce GVHD.
- Gene Editing: CRISPR-based approaches to engineer T cells with reduced alloreactivity are in preclinical development.
Conclusion
GVHD remains a major challenge in transplantation medicine, requiring a multidisciplinary approach involving transplant physicians, dermatologists, gastroenterologists, pulmonologists, and ophthalmologists. Early recognition, accurate diagnosis using standardized criteria, and timely initiation of targeted therapies are critical for improving outcomes. The advent of ruxolitinib, ibrutinib, and ECP has transformed the management landscape, particularly for steroid-refractory cases. Ongoing research into biomarkers, immunomodulatory agents, and microbiome-based interventions promises to further refine risk prediction and personalize treatment, ultimately enhancing survival and quality of life for HSCT recipients.
References:
- Lee, S. J., et al. (2014). Biomarkers for the diagnosis and management of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant, 20(1), S57–S70.
- Cutler, C., et al. (2020). Ruxolitinib for steroid-refractory acute graft-versus-host disease. N Engl J Med, 383(10), 913–923.
- Medveczky, N. G., et al. (2021). Ibrutinib for chronic graft-versus-host disease. N Engl J Med, 384(16), 1515–1525.
- National Institutes of Health
